Table 7.
Characteristics of studies about IL-17 (pg/mL) included in this meta-analysis.
| Author | Year | Country | Case | Control | NOS score | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SZ | M/F | Mean | SD | SZ | M/F | Mean | SD | ||||
| Pernet Hara [105] | 2016 | Brazil | 15 | 0/15 | 6.98 | 1.11 | 10 | 0/10 | 16.2 | 4.39 | 8 |
| Suzuki∗ [106] | 2011 | Japan | 56 | 25/31 | 147.39 | 113.83 | 30 | 2/28 | 154.52 | 117.99 | 7 |
| Afzal [107] | 2014 | Pakistan | 30 | 5/25 | 415.01 | 483.4 | 30 | 21/9 | 718.05 | 756.55 | 7 |
| Afzal∗ [107] | 2014 | Pakistan | 152 | 51/101 | 375.95 | 468.19 | 30 | 21/9 | 718.05 | 756.55 | 7 |
| Arababadi [108] | 2010 | Iran | 100 | 41/59 | 13.7 | 2.34 | 100 | 40/60 | 4.43 | 0.54 | 8 |
| Arababadi∗ [108] | 2010 | Iran | 100 | 38/62 | 0.94 | 0.29 | 100 | 40/60 | 4.43 | 0.54 | 8 |
| Liu∗ [109] | 2016 | China | 19 | 10/9 | 21.4 | 5.9 | 20 | 8/12 | 17.3 | 6.2 | 7 |
| Roohi [110] | 2014 | India | 38 | 19/19 | 6.61 | 4.97 | 40 | 22/18 | 6.22 | 4.64 | 8 |
| Zhan∗ [111] | 2015 | China | 30 | 14/16 | 42.24 | 67.7 | 30 | 14/16 | 9.33 | 8.15 | 8 |
| Kologrivova∗a [112] | 2014 | Russia | 35 | 17/18 | 100.83 | 42.7 | 24 | NR | 45.29 | 54.85 | 7 |
| Bilirb [113] | 2016 | Turkey | 33 | 15/18 | 466.1 | 183.075 | 33 | 15/18 | 205.2 | 67.725 | 6 |
| Bilir∗b [113] | 2016 | Turkey | 37 | 17/20 | 454.9 | 189.825 | 33 | 15/18 | 205.2 | 67.725 | 6 |
| Vasanthakumarc [114] | 2015 | India | 65 | 38/27 | 59.8 | 2.8 | 88 | 35/53 | 94.7 | 12.75 | 6 |
| Vasanthakumar∗c [114] | 2015 | India | 97 | 57/40 | 67.4 | 2.275 | 88 | 35/53 | 94.7 | 12.75 | 6 |
DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ∗T2DM with complication; adata converted from median (interquartile); bdata converted from median (range); cdata converted from geometrical mean (range).